Is it safe to combine Strattera (atomoxetine) with Adderall (mixed amphetamine salts)?

Combining Strattera and Adderall: Clinical Recommendation

Yes, combining Strattera (atomoxetine) and Adderall (amphetamine) can be done safely as an off-label adjunctive therapy when stimulant monotherapy provides inadequate symptom control, though this combination lacks FDA approval and has limited evidence compared to guanfacine or clonidine combinations. 1

Evidence-Based Framework for Combination Therapy

Guideline Support for Combination Use

The American Academy of Pediatrics (AAP) clinical practice guidelines explicitly acknowledge that atomoxetine can be used in combination with stimulant medications on an off-label basis when adjunctive therapy is needed. 1 However, only extended-release guanfacine and extended-release clonidine have sufficient evidence to achieve FDA approval for adjunctive use with stimulants. 1

The primary indication for adding atomoxetine to a stimulant is inadequate response to stimulant monotherapy or intolerable side effects that prevent optimal dosing. 2

Safety Profile of the Combination

Coadministration of methylphenidate with atomoxetine did not increase cardiovascular effects beyond those seen with methylphenidate alone. 3 This is the most direct safety data available from FDA labeling. 3

Both medications independently affect cardiovascular parameters:

• Stimulants increase heart rate by 1-2 beats per minute and blood pressure by 1-4 mm Hg on average, with 5-15% of patients experiencing more substantial increases. 1
• Atomoxetine also increases heart rate and blood pressure, requiring monitoring similar to stimulants. 1
• When combined, monitor vital signs closely as additive cardiovascular effects are theoretically possible, though the FDA label suggests this may not occur clinically. 3

Clinical Evidence for Efficacy

Real-world evidence shows mixed results:

• A 2015 study of 12 patients (ages 7-17) showed significant improvement with combined methylphenidate and atomoxetine, with Clinical Global Impression-Severity scores decreasing from 5.08 to 3.08 (p=0.03). 4 Nine of 12 patients showed significant symptom improvement. 4
• A 2013 systematic review found limited but suggestive evidence that combination therapy may benefit some patients who have tried several ADHD medications without success, though the evidence does not confirm universal benefit. 2
• The most common side effects in combination therapy were irritability (41.6%), appetite reduction (25%), palpitations (16.7%), and headache (8.3%). 4

Critical Safety Considerations

Before initiating combination therapy, obtain:

• Personal and family cardiac history including sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome. 1
• Consider obtaining an ECG if any cardiac risk factors are present. 1
• Baseline heart rate and blood pressure measurements. 1

Monitor throughout treatment:

• Heart rate and blood pressure at each visit, particularly during dose adjustments. 1
• Growth parameters in children and adolescents, as both medications can affect growth velocity. 1
• Suicidal ideation, as atomoxetine carries an FDA black box warning for increased suicidal thoughts. 1
• Hepatic function if any signs of liver injury develop (atomoxetine can rarely cause hepatitis). 1

Common Pitfalls to Avoid

Do not combine atomoxetine with amphetamines if the patient is taking MAOIs or has taken them within 14 days, as this is contraindicated. 3

Be aware of CYP2D6 poor metabolizer status: Approximately 7% of Caucasians and 2% of African Americans are poor metabolizers, resulting in 10-fold higher atomoxetine exposure and 5-fold higher peak concentrations. 3 This increases the risk of adverse effects when combined with stimulants. 3

Watch for emergent dyskinesias: A case series reported dyskinesias when atomoxetine was combined with dextroamphetamine and clonidine, though causality was unclear. 5 Clinicians should be vigilant for abnormal involuntary movements when combining these medications. 5

Avoid abrupt discontinuation of atomoxetine if the combination is not tolerated, as gradual tapering is preferred. 1

Treatment Strategy

Start atomoxetine at standard dosing (0.5 mg/kg/day initially, target 1.2 mg/kg/day in children/adolescents; 40 mg/day initially, target 80-100 mg/day in adults) while maintaining the current stimulant dose. 6 Atomoxetine takes longer to reach full effect than stimulants, with median time to 25% symptom improvement of 3.7 weeks and continued probability of improvement up to 52 weeks. 6

If the patient is a known or suspected CYP2D6 poor metabolizer, reduce the atomoxetine target dose to 0.5 mg/kg/day or 40 mg/day in adults. 3

Titrate slowly to minimize gastrointestinal side effects and somnolence, which are more common with rapid dose escalation. 1

When to Consider This Combination

Use this combination when:

• Stimulant monotherapy provides partial but insufficient symptom control. 1, 2
• Stimulant side effects prevent optimal dosing. 1, 2
• Extended-release guanfacine or clonidine (FDA-approved adjunctive options) are contraindicated or ineffective. 1
• The patient requires 24-hour symptom coverage and stimulant duration is insufficient. 6

Do not use this combination as first-line therapy; stimulant monotherapy remains the evidence-based first-line treatment for ADHD. 1, 7, 8